Multiple Sclerosis – Emerging Therapies – Lemtrada Launch Tracking Wave 1 (US)

LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved for the treatment of relapsing forms of multiple sclerosis (MS). This report series is based on primary research data collected at one month, three months, six months, and one year post-commercial availability of Lemtrada. Along with awareness and sources of familiarity, the reports assess U.S. neurologists’ trial, adoption, and usage of Lemtrada, including anticipated future trends. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Genzyme’s promotional efforts, and benchmarking against other previously launched MS agents.

Questions Answered:

  • Genzyme launched Lemtrada in the U.S. market as a treatment for relapsing forms of MS in December 2014. What is neurologists’ level of awareness and familiarity with Lemtrada over the course of the following year?
  • Lemtrada enters an increasingly crowded MS market with ten branded DMT options, four of which have entered in the past five years. What are the perceived clinical advantages and disadvantages of Lemtrada compared to other marketed agents used to treat MS? How is the trial and adoption of Lemtrada tracking compared with other recent product launches in the MS market?
  • Because of its safety profile, Lemtrada’s U.S. label recommends that it should generally be reserved for later-line use in the treatment of relapsing forms of MS. Where do neurologists expect Lemtrada to fit in the MS treatment algorithm? What are the current prescribing trends among DMTs, and how do neurologists anticipate they will change over the next six months?
  • Lemtrada is Sanofi/Genzyme’s second entrant into the MS market, following the companies’ 2012 launch of Aubagio. What promotional messages and activities are Genzyme employing in support of the Lemtrada launch?

Scope: 

Markets covered: United States.

Primary research: 74 neurologists surveyed per report Wave; 10 qualitative interviews with a subset of survey respondents.

Indication coverage: Relapsing-remitting MS.

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Lemtrada Launch Tracking Wave 1 (US)
    • Key Findings
      • Awareness and Perceptions of Lemtrada
      • Current Lemtrada Trial and Use
      • Competitive Landscape (Lemtrada Performance and Promotional Activity)
      • Anticipated Lemtrada Trial and Use
    • Benchmarking Lemtrada Launch Success vs. MS Analogs
      • Prescriber and Nonprescriber Profiles
        • Lemtrada: Differences Between Prescriber and Nonprescriber Profiles
        • Lemtrada: Differences Between Prescriber and Nonprescriber Profiles
      • Lemtrada Awareness and Perceptions
        • Unaided and Aided Awareness of Lemtrada
          • Familiarity with Lemtrada
            • Familiarity with Lemtrada: Prescribers vs. Nonprescribers
            • Awareness of Lemtrada Indication
            • Awareness of Lemtrada Administration
            • Awareness of Lemtrada Dosing Frequency
          • Sources of Familiarity with Lemtrada
            • Physician Quotes on Sources of Familiarity with Lemtrada
          • Initial Reaction to and Interest in Learning More About Lemtrada
            • Lemtrada Product Profile
            • Initial Reaction to Lemtrada
            • Interest Level in Lemtrada
          • Impressions of Lemtrada
            • Open-End Responses: Lemtrada Information Requiring Additional Education
            • Uniqueness of Lemtrada vs. Currently Available Treatments
            • Lemtrada Risk-Benefit Profile Balance
            • Open-End Responses: Unaided Advantages of Lemtrada
            • Open-End Responses: Unaided Disadvantages of Lemtrada
            • Qualitative Interview Follow-Ups
            • Statement Agreement Regarding Lemtrada
            • Statement Agreement Regarding Lemtrada
            • Clinical Interchangeability of Lemtrada and DMT Brands
          • Prescriber and Nonprescriber Profiles
            • Lemtrada: Differences Between Prescriber and Nonprescriber Profiles
            • Lemtrada: Differences Between Prescriber and Nonprescriber Profiles (cont.)
        • Lemtrada Trial and Use
          • Willingness to Prescribe Lemtrada
            • Lemtrada Trial
            • Qualitative Interview Follow-Ups
            • Lemtrada Attribute Impact on Willingness to Prescribe
            • Lemtrada Attribute Impact on Willingness to Prescribe
          • Number of Patients Currently Receiving Lemtrada
            • Mean Lemtrada Patient Volume Among Lemtrada Prescribers
            • Prescribed Lemtrada as Part of a Clinical Trial
            • Current Lemtrada Status
            • Lemtrada Prescribing by Disease Classification Among Current Prescribers
            • Lemtrada Patient Origination
            • Lemtrada Patient Origination
            • Course of Lemtrada Treatment Among Current Prescribers
            • Number of Treatments with DMTs Prior to Lemtrada
            • Percentage of Patients on Lemtrada Seen for Follow-Up
            • Response to Lemtrada Treatment
            • Infusion-Associated Reaction Severity to Lemtrada
            • Percentage of Physicians Receiving Patient Requests for Lemtrada in the Past Month
            • Action Based on Specific Lemtrada Patient Inquiries
          • Reasons for Not Yet Prescribing Lemtrada
            • Anticipated Timeframe to Initial Lemtrada Prescribing Among Nonprescribers
          • Anticipated Lemtrada Use
            • Potential Peak Share* for Lemtrada
            • Characteristics of Lemtrada Candidates
            • DMTs Preceding Lemtrada Treatment
            • DMTs Preceding Lemtrada Treatment
            • DMTs Preceding Lemtrada Treatment
          • Lemtrada Performance on Key Attributes
            • Lemtrada Performance Ratings and DMT Choice Attribute Importance Ratings
            • Lemtrada Performance Ratings and DMT Choice Attribute Importance Ratings
            • Overall Lemtrada Satisfaction: Lemtrada Prescribers
            • Open-End Responses: Overall Satisfaction with Lemtrada Among Prescribers
        • Effectiveness of Face-to-Face Detailing for Lemtrada
          • Lemtrada Sales Representative Frequency and Reach
            • Sales Representative Detailing Frequency
            • DMT Detailing Frequency Among All Surveyed Neurologists
          • Satisfaction with Lemtrada Sales Representative
            • Satisfaction Rating for Lemtrada Sales Representative Quality Attributes
            • Open-End Responses: Unaided Advice Regarding Lemtrada Promotion
          • Lemtrada Message Recall
            • Open-End Responses: Unaided Messages During Recent Lemtrada Detail
        • Appendix
          • Primary Market Research
            • Respondent Demographics
            • Years in Practice Post-Residency (percentage of neurologists)
            • U.S. Region of Practice (percentage of neurologists)
            • Practice Location (percentage of neurologists)
            • Practice Setting (percentage of neurologists)
            • MS Patient Volume Under Personal Management in Past Year
            • Patient Allocation by MS Disease Classification
          • Additional Information
            • Open-End Responses: Respondent Feedback
            • Open-End Responses: Recent Changes in Management/Treatment of MS Patients
            • Qualitative Interview Follow-Ups
            • RR-MS Patients Prescribed DMTs
            • Anticipated RR-MS DMT Treatment Rate: Next Six Months
            • Likely Actions Taken Upon Lemtrada Request
            • Likely Scenario Upon Referral
            • Lemtrada REMS Program Enrollment Status
            • Enrollment Process Rating
            • Open-End Responses: Lemtrada REMS Program Enrollment
            • Managed Care Approval Process
            • Open-End Responses: Perception of Lemtrada Managed Care Approval Process
            • Managed Care Requirements for Prescribing Lemtrada
            • Most Common DMT Failures MCOs Requested
            • Percentage of Lemtrada Prescriptions Denied tou2026
            • Value of Genzymeu2019s MS One to OneTM Program
            • MS Market Background
            • DMTs indicated for the treatment of relapsing forms of MS in the United States:
            • MS Market Background: Recent Commercial Launches
            • Objectives

      launch Related Market Assessment Reports